ER+, HER2- Early Breast Cancer

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating The Efficacy And Safety Of Adjuvant Giredestrant Compared With Physician’s Choice Of Adjuvant Endocrine Monotherapy In Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer

Schedule an Appointment

Select an appointment date and time from available spots listed below.